Comparison of hepatocellular carcinoma in Eastern versus Western populations.
Hepatocellular carcinoma (HCC) is a heterogeneous disease that remains highly prevalent in many Asian countries and is the second most common cause of cancer-related mortality worldwide. Significant differences exist between Eastern and Western populations on many key aspects of HCC, contributing to the potential different treatment outcomes and challenges of clinical trial design and data interpretation. In this review, the authors compare HCC in Asia versus the West and highlight 1) differences in terms of epidemiology and trends and their correlation with etiology, 2) differences in genetics and how they relate to underlying etiology, 3) differences in treatment approaches based on existing guidelines and consensus statements, and 4) differences in clinical outcomes for Asian versus non-Asian patients with HCC in clinical trials and the implications for future clinical trial design. Cancer 2016;122:3430-3446. © 2016 American Cancer Society.
Department of Medical Oncology, National Cancer Center, Singapore.
Su Pin
SP
Choo
Department of Medical Oncology, National Cancer Center, Singapore.
Wan Ling
WL
Tan
Department of Hepato-Pancreaticobiliary Surgery, Singapore General Hospital, Singapore.
Brian K P
BKP
Goh
Department of Medical Oncology, National Cancer Center, Singapore.
Wai Meng
WM
Tai
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Andrew X
AX
Zhu
Asian versus non-Asian; East versus West; hepatocellular carcinoma; liver cancer; regional differences